About
Pressroom
Resources
Get Updates
Issues
Access to Medicines
Funding the Fight
Health Justice
Transparency & Accountability
PEPFAR Watch
Blog
Our Impact
Take Action
Do something now
DONATE
Pharma Greed
Access to Medicines
Merck’s Molnupiravir – Overcoming impending barriers to affordable global access
Access to Medicines
Pfizer and BioNTech Profiteering Exposed – More than Enough is Enough
Access to Medicines
New ViiV license with the Medicines Patent Pool expands access but eviscerates transparency
Access to Medicines
Generic Licensing: the Only Path Through the Maze of Gilead and U.S. Patents that Achieves Access to Affordabl...
Access to Medicines
The President’s Trumpeteering on Drug Prices is Really a Toy Whistle
Access to Medicines
Drug Companies Getting Away with Murder – Trump’s Solution: Round Up Foreign Country Targets
Access to Medicines
Lies, Distortions, and False Promises: The U.S. Position on Compulsory Licenses in the 2018 Special 301 Report
Access to Medicines
Don’t Be Afraid of Compulsory Licenses Despite US Threats: Special 301 Reports 1998-2017 – Listing Concern...
Access to Medicines
Canada Blinks in Face of US/Pharma Pressure – Supreme Court Adopts Wink-Wink Patent Utility Rule
Access to Medicines
Trump’s Draft Executive Order on Pharmaceutical Pricing: Dangerous Medicine for Consumers at Home and Abroad
Access to Medicines
Trump’s Drug Pricing Executive Order is Likely to be an Unfettered Giveaway to Big Pharma: Insights from 201...
Access to Medicines
How activists transformed the TPP from a done-deal to dead-on-arrival
Access to Medicines
Durban Reflections #1: The Threat of Big Pharma’s Monopoly Unbound
Access to Medicines
U.S.’s Newest IP Gunship Diplomacy in Colombia – Same Threats with Dollars not Bullets
Access to Medicines
TPP = Transnational Pharmaceutical Profiteering
SEE MORE
